US › Healthcare

Neuphoria Therapeutics Inc (NEUP)

US · Healthcare · Biotechnology

$3.71-0.67%

Last close · 2026-09-17

Latest quarter · ended 2026-03-31

Revenue

Revenue YoY

-100.0%

Net profit

$-505,063

Profit YoY

-104.5%

EPS

$-0.09

EPS estimate

$-0.56

EPS came in at -0.09 against a street estimate of -0.56 — a beat of 83.9%.

Key statistics

Market cap

$20.4M

Forward P/E

0.0

P/B

0.69

Book value

$5.47

EPS (TTM)

$-7.96

52-week high

$21.40

52-week low

$3.19

50-day MA

$3.74

200-day MA

$4.26

Analyst view

Analysts rate Neuphoria Therapeutics Inc a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $7.00.

Shareholding

Insiders

7.70%

Institutions

61.41%

Largest institutional holders

Fund	Stake
Lynx1 Capital Management, LP	16.20%
AdvisorShares Investments, LLC	4.68%
Shay Capital LLC	2.79%
Balyasny Asset Management LLC	2.63%
Vanguard Capital Management, LLC	1.82%
Citadel Advisors Llc	1.34%
Geode Capital Management, LLC	0.96%
Ikarian Capital, LLC	0.88%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neuphoria Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.